NASDAQ:NBIX - Neurocrine Biosciences Stock Price, News, & Analysis

$84.76
-0.24 (-0.28 %)
(As of 06/24/2019 03:19 PM ET)
Today's Range
$84.47
Now: $84.76
$85.75
50-Day Range
$74.65
MA: $81.06
$86.62
52-Week Range
$64.72
Now: $84.76
$126.98
Volume17,727 shs
Average Volume652,981 shs
Market Capitalization$7.74 billion
P/E Ratio386.27
Dividend YieldN/A
Beta1.45
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$451.24 million
Cash Flow$0.4999 per share
Book Value$5.30 per share

Profitability

Net Income$21.11 million

Miscellaneous

Employees585
Market Cap$7.74 billion
Next Earnings Date7/30/2019 (Estimated)
OptionableOptionable

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings results on Monday, April, 29th. The company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $0.07. The company earned $138.40 million during the quarter, compared to the consensus estimate of $136.77 million. Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The business's revenue was up 94.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.47) earnings per share. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

19 equities research analysts have issued 1-year price targets for Neurocrine Biosciences' stock. Their forecasts range from $17.07 to $135.00. On average, they expect Neurocrine Biosciences' stock price to reach $102.8372 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

What is the consensus analysts' recommendation for Neurocrine Biosciences?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

What are Wall Street analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:
  • 1. According to Zacks Investment Research, "Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. " (4/30/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $102/share is based on an equally weighted composite of: (a) $103/share, as a 35x multiple of taxed and diluted FY25 GAAP EPS of $8.80 discounted back to and (b) an NPV of $101/share (discount rate 10%, growth rate 2%). We base our valuation on a 20% royalty on sales for Elagolix in endometriosis and uterine fibrosis (probability adjusted). For valbenazine, we include the indication of TD. For opicapone, we include the US revenue (63% goes to 85% POS." (1/30/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $121 PT on NBIX. Voyager (VYGR, NC) announced a collaboration to develop four of Voyager’s assets, including those for Friedrich’s Ataxia. We believe this deal brings value to both partners, allowing Neurocrine to expand its platform to innovative gene therapy treatments, while it continues to focus on realizing clinical and commercial synergies in movement disorders (and also possibly to expand to additional indications that may be served by Voyager’s platform). We also opine that Voyager benefits from a partner with significantly more resources and expertise in clinical development and commercialization." (1/29/2019)

Has Neurocrine Biosciences been receiving favorable news coverage?

Media coverage about NBIX stock has been trending positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a news impact score of 2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Neurocrine Biosciences.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), Celgene (CELG), Sarepta Therapeutics (SRPT), Netflix (NFLX), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (9.66%), First Trust Advisors LP (1.19%), Pictet Asset Management Ltd. (1.07%), Marshall Wace North America L.P. (0.64%), Victory Capital Management Inc. (0.59%) and Jennison Associates LLC (0.45%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Marshall Wace LLP, GAM Holding AG, First Trust Advisors LP, Frontier Capital Management Co. LLC, Bank of Montreal Can, California Public Employees Retirement System and Braun Stacey Associates Inc.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Dimitri E Grigoriadis, Eiry Roberts, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Richard F Pops. View Insider Buying and Selling for Neurocrine Biosciences.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Rockefeller Capital Management L.P., Westfield Capital Management Co. LP, Rothschild & Co. Asset Management US Inc., Pictet Asset Management Ltd., Fosun International Ltd, Rice Hall James & Associates LLC and Raymond James & Associates. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $84.76.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $7.74 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  773 (Thanks for Voting!)
Underperform Votes:  227 (Thanks for Voting!)
Total Votes:  1,000
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel